Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
2008
Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
1999
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival
2014 StandoutNobel
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Why do cancers have high aerobic glycolysis?
2004 Standout
Testicular Germ-Cell Cancer
1997 Standout
Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment
2007
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)
2001
Conventional fractionated radiation therapy vs. radiosurgery for selected benign intracranial lesions (arteriovenous malformations, pituitary adenomas, and acoustic neuromas)
1993
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Integrins in cancer: biological implications and therapeutic opportunities
2009 Standout
Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type
1999
Cellular senescence in aging and age-related disease: from mechanisms to therapy
2015 Standout
Drug discovery from natural sources
2006
Cushing's syndrome
2015 Standout
Factors affecting sensitivity and specificity of a diagnostic test: the exercise thallium scintigram
1988
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Exercise Standards for Testing and Training
2013 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma
2001
The role of positron emission tomography (PET) in the management of lymphoma patients
1999
Brain Endothelial Cells as Pharmacological Targets in Brain Tumors
2004
Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
2006
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Regulation of cancer cell metabolism
2011 Standout
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
2013 Standout
The usefulness of 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and a comparison of 18F‐FDG‐pet with 67gallium scintigraphy in the evaluation of lymphoma
2007
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors
2004
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma
2002
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Transcriptional Repression of Protein Kinase Cα via Sp1 by Wild Type p53 Is Involved in Inhibition of Multidrug Resistance 1 P-Glycoprotein Phosphorylation
2004
Increased incidence of sarcoma in patients treated for testicular seminoma
1993
Cardiotoxic Effects of Tangential Breast Irradiation in Early Breast Cancer Patients: The Role of Irradiated Heart Volume
2007
Radiation Dose–Volume Effects in the Heart
2010
Correlation between the tumoral expression of β3-integrin and outcome in cervical cancer patients who had undergone radiotherapy
2004
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Tomographic imaging using the nonlinear response of magnetic particles
2005 StandoutNature
18p-FDG PET is superior to67Ga SPECT in the staging of non-Hodgkin’s lymphoma
2004
Anthracycline drug targeting: cytoplasmic versus nuclear – a fork in the road
2001
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma
1996
Tumor Angiogenesis
2008 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
Senescence and apoptosis: dueling or complementary cell fates?
2014
Second Primary Malignancy Risk in Thyroid Cancer Survivors: A Systematic Review and Meta-Analysis
2007
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases
1999
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Positron Emission Tomography Scanning: Current and Future Applications
2002
The Risk of Second Primary Malignancies up to Three Decades after the Treatment of Differentiated Thyroid Cancer
2007
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
2001
Angiogenesis as a Therapeutic Target in Malignant Gliomas
2009
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study
2006
Targeting G βγ signaling in arterial vascular smooth muscle proliferation: A novel strategy to limit restenosis
1999 StandoutNobel
Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases.
2003
Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
2001
Nonoperative Dilatation of Coronary-Artery Stenosis
1979 Standout
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
2004 StandoutNobel
Measurement of Fractional Flow Reserve to Assess the Functional Severity of Coronary-Artery Stenoses
1996 Standout
Radiation therapy for neoplasms of the brain
1987
Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma
2002
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
2002
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
2003
The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.
2005
Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
2001
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
The Chemistry of Neutron Capture Therapy
1998 Standout
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
An evidence‐based review of poorly differentiated thyroid cancer
2007
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis.
1989
Utility of FDG-PET scanning in lymphoma by WHO classification
2003
Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).
1988 Standout
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
2005
Thyroid carcinoma
2003 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Works of C Glanzmann being referenced
[Methodology of myocardial scintigraphy with thallium 201: limits of pathological findings].
1977
[1 year's experiences with the 201 thallium myocardial scintigraphy for the evaluation of coronary circulation disorders].
1977
[Cerebral arterio-venous malformations (avm): course of 18 cases treated by radiotherapy (author's transl)].
1978
Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells
1999
Long-term morbidity of adjuvant infradiaphragmatic irradiation in patients with testicular cancer and implications for the treatment of stage I seminoma
1991
Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
2001
Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography
1998
The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
2001
Cardiac lesions after mediastinal irradiation for Hodgkin's disease
1994
Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway.
2000
Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
2001
[Therapy of the metastasizing adenocarcinoma of the thyroid gland using 131-I. Experiences with 103 patients from 1963 to 1977 (author's transl)].
1979
Considerations in the radiation treatment of intracranial ependymoma. Prognosis in 24 own cases and results in published series after different techniques of radiation treatment.
1980
Subsequent malignancies in patients treated with 131-iodine for thyroid cancer.
1992
Long-term follow-up of 92 patients with locally advanced follicular or papillary thyroid cancer after combined treatment.
1992